When was AxoGen founded?

AxoGen was founded in 2002 and raised its 1st funding round 5 years after it was founded.

Where is AxoGen located?

AxoGen is headquartered in Alachua, United States.

How many employees does AxoGen have?

As of Dec 28, 2025, the latest employee count at AxoGen is 560.

Is AxoGen a funded company?

AxoGen is a funded company, having raised a total of $62.4M across 11 funding rounds to date. The company's 1st funding round was a $***** Series C round, raised on Dec 04, 2007.

When was the latest funding round of AxoGen?

AxoGen's latest funding was a $***** Conventional Debt round on Oct 26, 2016, with participation from 0 investor.

What is the annual revenue of AxoGen?

Annual revenue of AxoGen is $225M as on Dec 31, 2025.

Where does AxoGen rank among its competitors?

AxoGen ranks 3rd amongst 46 active competitors, of which 12 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Tissue Regenix, which secured $10.1M in Dec, 2025.

Who are the top competitors of AxoGen?

AxoGen's top competitors include Humacyte, CUTISS and Acera Surgical. Among them, Tissue Regenix secured the most recent funding round in December, 2025.

AxoGen - 2026 Company Profile, Team, Funding & Competitors

AxoGen is a public company based in Alachua (United States), founded in 2002 by John Engels. It operates as a Developer of therapies for the repair of peripheral nerve injuries. AxoGen has raised $62.4M in funding. The company has 46 active competitors, including 12 funded and 14 that have exited. Its top competitors include companies like Humacyte, CUTISS and Acera Surgical.

Company Details

Developer of therapies for the repair of peripheral nerve injuries. The flagship product is the AVANCE Nerve Graft, a human allograft nerve for treating damaged peripheral nerves. Other products include AxoGuard Nerve Connector and Protector (extracellular matrices), and AxoTouch Two-Point Discriminator tool, a set of two aluminum discs to measure sensation after a nerve injury.

Website: www.axogeninc.com/
Social

Key Metrics

Founded Year

2002

Location

Alachua, United States

Stage

Public

Total Funding

$62.4M in 11 rounds

Latest Funding Round

Conventional Debt, Oct 26, 2016, $*****

Investors

Oberland Capital & 10 more

Ranked

3^rd among 46 active competitors

Annual Revenue

$225M as on Dec 31, 2025

Employee Count

560 as on Dec 28, 2025

Similar Companies

Humacyte & 53 more

Exit Details

Public

View AxoGen's full profile

AxoGen is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Axogen, Inc. CIN: 805928 , United States, Active		$225M (As on Dec 31, 2025)	-	-
Axogen Corporation CIN: 550805988 , United States, Active	Jun 12, 2006	-	448 (As on Dec 31, 2024)	-
Axogen, Inc. CIN: 41-13018 , United States, Active	Jan 01, 1987	-	428 (As on Dec 31, 2023)	-

AxoGen got listed on Dec 19, 1986.

Click here to take a look at AxoGen's IPO in detail

AxoGen has raised a total funding of $62.4M over 11 rounds. Its first funding round was on Dec 04, 2007. AxoGen has 11 institutional investors.

Here is the list of recent funding rounds of AxoGen:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 26, 2016	2475285	Conventional Debt	3152650	8105878	4927936	6738588
Aug 26, 2015	1352968	Series D	9632049	8985073	4634125	EW Healthcare Partners
Nov 13, 2014	8540896	Series D	1788615	4432263	9160712	Oberland Capital

Access funding benchmarks and valuations. Sign up today!

View details of AxoGen's funding rounds and investors

The founders of AxoGen is John Engels. Karen Zaderej is the CEO of AxoGen.

Here are the details of AxoGen's key team members:

John Engels: Founder of AxoGen. They are also an angel investor in 1 startup.

View details of AxoGen's Founder profiles and Board Members

AxoGen's employee count trend

AxoGen has 560 employees as of Dec 25. Here is AxoGen's employee count trend over the years:

Uncover AxoGen's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AxoGen include Humacyte, CUTISS and Acera Surgical. Here is the list of Top 10 competitors of AxoGen, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Humacyte 2004, Morrisville (United States), Public	Provider of human tissue-based products for vascular disease	$425M	Access Industries, Fresenius Medical Care ... & 13 others	66/100
2nd	CUTISS 2017, Zurich (Switzerland), Series C	Skin grafts for treatment of burns, cuts and damaged skin	$157M	Cherry Bay Capital Group, Rode Kruis Ziekenhuis ... & 14 others	65/100
3rd	AxoGen 2002, Alachua (United States), Public	Developer of therapies for the repair of peripheral nerve injuries	$62.4M	Oberland Capital, Cardinal Partners & 9 others	65/100
4th	Acera Surgical 2013, St. Louis (United States), Acquired	Provider of synthetic electrospun scaffolds for regenerative medical applications	$6.32M	St. Louis Arch Angels, Missouri Technology ... & 1 others	57/100
5th	Tulavi Nerve Therapeutics 2020, Mountain View (United States), Series A	Developer of the therapeutic device to treat neurally mediated diseases	$11.5M	Ascension Ventures, Delos Capital Partners ... & 1 others	56/100
6th	RxFunction 2010, Minneapolis (United States), Series B	Provider of wearable prosthesis for people with sensory peripheral neuropathy	$39.9M	HHS & 1 others	52/100
7th	Aroa Biosurgery 2008, Mangere (New Zealand), Public	Developer of medical and surgical products for soft tissue reconstruction	-	Alium Capital, Cure Kids Ventures & 2 others	47/100
8th	Tissue Regenix 2006, Swillington (United Kingdom), Public	Developer of regenerative medical devices by using cell technology	-	Harwood Capital, Aquarius Equity Partners ... & 2 others	47/100
9th	Heartseed 2015, Shinjuku City (Japan), Public	Developer of myocardial regenerative medicine for treating heart diseases	$76.7M	Sumitomo Mitsui Trust Holdings, SMBC Venture Capital ... & 18 others	46/100
10th	ACell 1999, Lafayette (United States), Acquired	Develops wound management devices using ECM technology	$8.7M	-	44/100